FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety

The short version: On April 15, 2026, the FDA announced it will convene an advisory panel in July to review seven restricted peptides — including BPC-157 and TB-500 — and decide whether they can be legally compounded again. This is not an approval announcement. It is the beginning of a formal regulatory process, and patients deserve to understand exactly what that difference means.

What the FDA Just Announced — And Why It Matters

The Food and Drug Administration made a significant regulatory move on April 15, 2026: it issued a federal notice confirming that an outside panel of pharmacy advisers will meet this coming July to evaluate seven peptide compounds currently classified under the agency's most restrictive compounding category. Specifically, the panel will assess whether those substances should be moved off the Category 2 list — a designation reserved for bulk drug substances that present potential safety risks and are therefore ineligible for routine compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

For patients and clinicians who have followed the peptide regulatory saga since 2023, this announcement carries weight. For those just tuning in, the context matters enormously — because without it, the headlines can be wildly misleading.

This is not an FDA approval of peptides. It is not a green light. It is a public advisory process, one that could eventually lead to restored compounding access for some substances, but through a multi-step regulatory pathway that will take months — possibly longer — to resolve.

The announcement follows a sustained public push by Health and Human Services Secretary Robert F. Kennedy Jr., who has repeatedly stated his support for loosening restrictions on peptides. During an appearance on Joe Rogan's podcast, Kennedy described himself as "a big fan of peptides," adding that he had used them personally "with really good effect on a couple of injuries." He previewed this federal notice weeks before it was issued. That political backdrop is part of the story, and patients should be aware of it as they evaluate what comes out of July's meeting.

What Is the FDA's Pharmacy Advisory Committee (PCAC)?

The Pharmacy Compounding Advisory Committee is a panel of outside scientific and clinical advisers who provide the FDA with independent recommendations on compounding-related questions. Their votes are not binding — the FDA retains final authority — but they carry significant regulatory influence. Notably, the panel currently has several vacancies, which Kennedy could fill with new appointments before the July meeting, a detail that has drawn concern from regulatory oversight advocates.

The Seven Peptides Under Review

This is the most-searched question surrounding this announcement, and it deserves a clear, compound-by-compound answer.

The FDA confirmed that BPC-157 and TB-500 are among the seven peptides under review, alongside five others. Based on the federal notice and prior regulatory filings, the substances under consideration are drawn from the broader list of peptides that were placed on the Category 2 restricted list beginning in 2023. Here is what patients and clinicians need to know about the primary candidates:

BPC-157 (Body Protection Compound-157)

BPC-157 is a synthetic pentadecapeptide — a 15-amino acid chain — originally derived from a protein found in gastric juice. It became one of the most widely used compounds in compounding pharmacy practice before the 2023 restrictions, prescribed for musculoskeletal healing, gut inflammation, tendon repair, and recovery from soft-tissue injuries.

The preclinical data on BPC-157 is genuinely interesting. Animal studies have shown accelerated healing of tendons, ligaments, and intestinal tissue, with proposed mechanisms involving growth hormone receptor signaling, nitric oxide pathways, and angiogenesis (the formation of new blood vessels). A 2024 systematic review published in a peer-reviewed orthopaedic journal acknowledged these findings while flagging a critical limitation: there are no completed Phase III clinical trials in humans. Several human studies appear to have been cancelled or stopped without published results — a gap that cannot be glossed over clinically [1].

Self-reported adverse effects from patients who used BPC-157 before the restrictions include injection site pain, joint discomfort, anxiety, heart palpitations, insomnia, fatigue, and mood changes. These are not rare anecdotes — they appear consistently across patient forums and in clinical observations. Whether they reflect dose-related issues, sourcing variability, or true pharmacological effects is unknown, precisely because the human data does not exist to answer that question.

BPC-157 is banned by the World Anti-Doping Agency (WADA) under its S0 category of unapproved substances, and is prohibited by the NCAA, NFL, NBA, NHL, and most major professional sports organizations.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide involved in actin regulation and cellular repair. It has been studied — primarily in animal models — for wound healing, tissue repair, reduction of inflammation, and recovery from cardiac injury. Like BPC-157, it has a substantial following in athletic and biohacking communities.

TB-500 is also banned by WADA and most professional sports leagues. Human clinical trial data remains sparse, and the compound shares much of BPC-157's regulatory history: popular before 2023, restricted under Biden-era FDA action, and now under consideration for reinstatement.

AOD-9604

AOD-9604 is a modified fragment of human growth hormone (hGH), originally studied by pharmaceutical company Metabolic Pharmaceuticals as a potential anti-obesity compound. It completed Phase IIb clinical trials but failed to demonstrate sufficient efficacy for weight loss to secure approval. It has since circulated in the compounding market as a fat metabolism aid, though no approved clinical indication exists.

Thymosin Alpha-1

This is perhaps the most clinically defensible peptide on the list. Thymosin Alpha-1 is an immune-modulating compound that is formally approved as a pharmaceutical product in more than 30 countries — including Italy, China, and several Southeast Asian nations — for the treatment of hepatitis B, hepatitis C, and as an immune adjuvant in oncology. The U.S. market lags significantly here. Its inclusion in the Category 2 restricted list has drawn criticism from clinicians who point to its legitimate international approval record as evidence that the safety concerns cited by the FDA are inconsistent with the global clinical literature.

CJC-1295 and Ipamorelin

These two growth hormone-releasing peptides are often prescribed together. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue — meaning it stimulates the pituitary to release growth hormone with fewer off-target effects than older compounds. They have been used clinically for muscle preservation, metabolic health, and sleep quality. Neither has completed the FDA's drug approval pathway.

The Remaining Substances

The FDA's notice confirms seven compounds total. Depending on the final federal register language, additional peptides from the 2023 restricted list — such as Selank, Semax, or KPV — may also fall within scope. Patients should monitor the official FDA docket for the confirmed, complete list as the July meeting date approaches.

How Did We Get Here? A Timeline of FDA Peptide Restrictions

Understanding the July meeting requires understanding the regulatory sequence that produced it.

2020–2022: Compounding pharmacies across the U.S. routinely dispensed injectable peptide therapies — BPC-157, TB-500, CJC-1295, Ipamorelin, and others — to patients with valid prescriptions from licensed physicians. The practice existed in a regulatory gray zone but was not actively prohibited.

Late 2023: The FDA took formal action, placing approximately 17 to 19 peptides in the Category 2 classification, which effectively prohibited their compounding under Section 503A. The agency cited safety risks including potential carcinogenicity, immunogenicity, and concerns about impurities — and noted that most of these substances had never undergone rigorous human clinical trials. The FDA's own advisory panel voted overwhelmingly that the peptides did not meet the criteria for safe compounding. Internal FDA staff agreed.

2024: The restrictions held, but pushback intensified. Compounding pharmacy trade groups, wellness entrepreneurs, and members of Congress — including Senator Tommy Tuberville of Alabama — pressured the incoming administration to reverse course. The compounding industry argued, not unreasonably, that the restrictions had driven patients toward unregulated gray-market sources: overseas chemical suppliers operating under "research use only" labels with no quality controls, no dosage verification, and no pharmaceutical oversight.

February 27, 2026: During his appearance on the Joe Rogan Experience (Episode 2461), HHS Secretary Kennedy announced that approximately 14 of the 19 restricted peptides would be moved back to Category 1, restoring a legal pathway for licensed compounding pharmacies. No formal FDA rule had been published as of that date. The announcement was a political signal, not a regulatory action.

April 15, 2026: The FDA issued its official federal notice scheduling the July advisory meeting. The agency also indicated it would soon remove the seven flagged compounds from the Category 2 restricted list in the interim — a provisional measure that patients should not interpret as formal approval.

Understanding the FDA's Compounding Category System

For non-clinical readers, the three-tier classification is worth spelling out plainly:

Category 1 substances can be legally compounded by licensed 503A pharmacies (individual prescription-based) and 503B outsourcing facilities (larger-scale production). A Category 1 designation means there is sufficient evidence to support safe compounding — not that the compound is FDA-approved as a drug.

Category 2 substances have been identified as presenting potential safety risks. They are currently ineligible for routine compounding. This does not mean they are illegal to possess; it means a pharmacy cannot legally prepare them for a patient, even with a prescription.

Category 3 substances lack sufficient data for a full evaluation and remain under review.

The critical point — and the one most frequently misunderstood in online discussions — is that compounding eligibility is not the same as FDA drug approval. A compounded peptide that moves from Category 2 to Category 1 is not an FDA-approved drug. It has no approved indication, no standardized dosing, and no manufacturer-backed clinical data. It is simply a substance that a licensed pharmacy may legally prepare for a patient who has received a prescription from a licensed provider.

Are Peptides FDA-Approved? What the 2026 List Actually Shows

This question: Are peptides approved by the FDA? — is among the most searched phrases around this topic, and it deserves a direct, unambiguous answer.

Yes, some peptides are FDA-approved. Most are not.

The peptides that dominate the wellness and biohacking conversation are largely not FDA-approved drugs. But the category of "peptides" is broad enough to include some of the most successful therapeutics in modern medicine.

The Peptides the FDA Has Formally Approved

1. GLP-1 receptor agonists 

Including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are peptide-based drugs that have completed full FDA review and carry approved indications for type 2 diabetes and obesity. They represent what rigorous clinical development looks like: Phase I through Phase III trials, post-marketing surveillance, and manufacturer accountability. At Meto, we work with patients on both these medications regularly, and the difference between an FDA-approved GLP-1 and an uncharacterized compounded peptide is not minor — it is fundamental. If you're on a GLP-1 medication and want to understand what labs should accompany it, this clinical guide to GLP-1 biomarker monitoring is a helpful reference.

2. Insulin 

Insulin and its analogues are peptide hormones. So are many drugs used in endocrinology, reproductive medicine, and oncology — including leuprolide (prostate cancer), oxytocin (labor induction), and vasopressin analogues (diabetes insipidus). The FDA-approved peptide landscape is actually quite large.

3. Sermorelin 

A growth hormone-releasing hormone analogue is worth specific mention because it remains in a distinct regulatory category from the substances under July review. Sermorelin is a separate compound with its own regulatory history and prescribing context.

What is not on the FDA's approved list: BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, Thymosin Alpha-1 (in the U.S.), and the other compounds under July review. If compounding access is restored for these substances, they will still not be FDA-approved drugs. That distinction matters for patient safety, liability, and informed consent.

The Gray Market Problem — And Why This Meeting Still Matters

One of the more substantive arguments made by compounding pharmacy advocates is empirical rather than political: restricting legal compounding did not eliminate patient demand. It redirected it.

Patients who had been using physician-prescribed peptide therapies didn't stop; many began sourcing from unregulated suppliers — overseas chemical vendors selling "research use only" compounds with no pharmaceutical manufacturing standards, no purity verification, no dosage accuracy, and no clinical oversight. Between 12% and 58% of unregulated supplement and research chemical products have been found to be contaminated with other substances, according to published literature [2]. That is a real risk — arguably a greater one than the theoretical risks the FDA cited when it enacted the 2023 restrictions.

From a strictly harm-reduction standpoint, restoring legal compounding access under physician oversight is arguably safer than maintaining a black-market status quo. This is a reasonable position, and it is one of the arguments the July panel will need to weigh carefully against the absence of rigorous human trial data.

What Experts and Scientists Are Actually Saying

Coverage of this topic has been heavy on political narrative and light on the underlying scientific debate. Here is where credible expert opinion actually falls.

The regulatory skeptics are not fringe voices. Dr. Peter Lurie, a former FDA official who now directs the Center for Science in the Public Interest, described allowing peptides to market without clinical testing as a "profound threat" to the FDA's decades-long drug vetting system. His concern is structural: if compounding eligibility becomes a commercially viable alternative to the full drug approval pathway, pharmaceutical developers will have a financial incentive to bypass Phase III trials entirely. "I don't see why one would take the path of a proper drug approval if there is now this less rigorous, alternative path to market," he said. Dr. Eric Topol of Scripps Research Translational Institute was more direct: "These peptides have no data to support their safety and efficacy."

The clinical proponents argue that the FDA's safety concerns — immunogenicity risk, impurity risk, organ toxicity — are theoretically valid but speculative in practice. They point to the fact that FDA-approved biologic drugs carry comparable immunogenicity risks that are accepted under clinical monitoring. They argue that the appropriate response is not a blanket ban but a structured framework: quality-controlled compounding, mandatory prescriber oversight, and data collection that builds the evidence base over time. Thymosin Alpha-1's approval record in more than 30 countries is frequently cited as evidence that the FDA's risk characterization is inconsistent with global clinical experience.

The scientific literature occupies an uncomfortable middle ground. BPC-157's preclinical record in animal models is genuinely compelling — the healing mechanisms proposed are biologically plausible and well-described [1]. But compelling preclinical data does not translate reliably to human outcomes. The history of medicine is full of compounds that healed rodents and harmed people. Without human trial data, clinicians and patients are making decisions based on incomplete information, and the self-reported adverse effect profile — anxiety, palpitations, insomnia, fatigue — is not benign enough to ignore.

What Happens After the July 2026 Meeting?

The July meeting is a beginning, not an end. Patients expecting immediate access to legal compounded peptides following the advisory panel vote should understand the process that follows.

Step 1 — Advisory Panel Vote: The outside panel assesses each of the seven compounds and votes on whether they should be eligible for compounding under 503A. Votes are not binding.

Step 2 — FDA Review of Recommendations: The FDA considers the panel's conclusions alongside internal review. The agency can accept, modify, or reject the panel's vote.

Step 3 — Draft Rule Publication: If the FDA agrees to reclassify compounds, it must draft and publish formal regulatory language — a process that takes additional months.

Step 4 — Public Comment Period: Any proposed rule is subject to a federal public comment period before it becomes final.

Step 5 — Final Rule Implementation: Only after a final rule is published and effective can licensed compounding pharmacies legally prepare the reclassified substances.

Scott Brunner of the Alliance for Pharmacy Compounding has described this as the start of a "protracted process." Even under the most optimistic scenario, broad clinical availability of legally compounded versions of these peptides is likely a mid-to-late 2026 proposition at the earliest — and possibly longer if the political or regulatory environment shifts.

The FDA has indicated it will remove the seven compounds from the interim Category 2 restricted list while the July review proceeds. Some compounding pharmacies may begin preparing certain compounds ahead of the formal rule based on this interim signal. Patients should be aware that this is an unsettled zone and should work only with licensed providers who are monitoring the formal regulatory status in real time.

Meto's Perspective: What We Think Patients Deserve to Know

At Meto, our clinical focus is on metabolic and hormonal health — the kind of deep, root-cause medicine that requires real diagnostics, physician oversight, and evidence-based treatment protocols. That context shapes how we read this regulatory moment.

We think the July meeting is genuinely significant. We also think it is being discussed in ways that do patients more harm than good.

On the access question: We believe patients who have legitimate clinical needs — documented injury, inflammatory conditions, immune dysfunction — deserve access to evidence-informed therapeutics through licensed, supervised channels. The gray market alternative is not a neutral status quo. Patients sourcing unverified peptide compounds from overseas vendors without physician oversight are exposed to real contamination risks, dosing inaccuracies, and the absence of any clinical safety net. If the July meeting results in a structured, prescription-only compounding framework with appropriate quality standards, that is a net improvement for patient safety regardless of where one sits politically on the question of regulatory scope.

On the approval question: We will be direct here, because the internet has not been: none of the peptides under July review are FDA-approved drugs, and they will not become FDA-approved drugs as a result of this meeting. The distinction matters enormously in a clinical setting. An FDA-approved drug comes with a defined indication, a validated dosing protocol, a safety surveillance system, and manufacturer accountability. A compounded peptide — even a legally compounded one — carries none of those structures. Patients have the right to make informed choices, and informed choice requires accurate information.

On the evidence question: The absence of Phase III human trial data for compounds like BPC-157 and TB-500 is a genuine clinical limitation, not a technicality. We would welcome a regulatory framework that restores access while simultaneously creating a pathway for real clinical data collection. The best outcome from July's meeting is not simply "yes" or "no" on compounding eligibility — it is a regulatory posture that treats these compounds with the scientific rigor their biological plausibility warrants.

What we tell our patients: If you are considering peptide therapy, speak with a licensed clinician who can assess your specific health situation, explain the current regulatory status accurately, and — if a peptide protocol is appropriate — ensure it is obtained through a verifiable, quality-controlled pharmacy. Never source injectables from unregulated vendors. And monitor your metabolic health comprehensively: a thorough comprehensive metabolic panel provides baseline liver, kidney, and glucose data that is essential context for anyone adding any new compound to their protocol.

We will continue tracking the July meeting and will update this article following the advisory panel's vote.

What Patients Should Know and Do Right Now

Regardless of what comes out of July's meeting, several practical realities apply to patients today.

If you are currently using compounded peptides sourced from a licensed U.S. pharmacy that resumed production following the February 2026 announcement: understand that you are in a transitional regulatory zone. Your pharmacy should be able to clarify its legal basis for compounding these substances. If they cannot, that is a significant red flag.

If you have been sourcing from gray-market or "research use only" vendors: The risks are real and not hypothetical — contamination, inaccurate dosing, and the absence of any clinical oversight. The fact that many people use these products without visible harm does not mean the risks are negligible. It means the harms are often delayed, attributed to other causes, or simply not reported.

If you have never used peptides and are curious: Wait. The July meeting will produce a clearer regulatory picture. Until then, work with a provider who understands your metabolic and hormonal baseline. Conditions like insulin resistance, thyroid dysfunction, and hormonal imbalance — the very issues Meto's clinical programs address — are well-established drivers of the symptoms (fatigue, poor recovery, body composition changes) that many people turn to peptides hoping to resolve. Root-cause metabolic care, supported by proper lab work, frequently addresses those drivers more durably than any single compound.

Questions to Ask Your Provider If You're Considering Peptide Therapy

• What is the current legal status of this compound under FDA compounding rules?
• Where will the compound be sourced, and what quality standards does the pharmacy meet?
• What is the clinical rationale for this compound in my specific case?
• What monitoring protocol do you use for patients on this therapy?
• What human clinical trial data exists to inform dosing and safety expectations?
• How does this fit within my broader metabolic and hormonal health plan?

A provider who cannot answer these questions clearly is not a provider who should be prescribing peptide therapies.

The Bigger Picture: Why This Moment Matters Beyond Peptides

The July meeting is not only about the seven compounds on the agenda. It is about the FDA's regulatory philosophy for an entire class of biologically active substances at a time when that class is expanding rapidly.

The GLP-1 revolution has fundamentally altered public perception of peptide-based medicine. Semaglutide and tirzepatide — both peptides, both rigorously approved — demonstrated that this class of molecule can produce transformative clinical outcomes. That success has raised legitimate curiosity about what other peptides might offer. It has also created a cultural moment in which the public conflates "peptide" with "effective" without the scientific scaffolding that makes GLP-1 drugs credible. For a deeper look at what GLP-1 approval actually required, Meto's clinical overview of GLP-1 drugs provides useful context — as does our recent piece on Foundayo (orforglipron), the first oral GLP-1 to reach approval.

Simultaneously, the supplement industry is moving to incorporate peptides into products — capsules, protein powders, gummies — under a regulatory framework that requires far less oversight than the compounding pathway. The FDA's decisions in July will ripple across that market as well.

The stakes for regulatory precedent are real. If the advisory panel recommends, and the FDA agrees, that compounding eligibility should be determined primarily by market demand and political pressure rather than clinical evidence, the integrity of the drug approval system faces a meaningful structural challenge. That is not a fringe concern — it is the explicit worry of experienced former FDA officials who have spent careers building the evaluation standards that protect patients.

At the same time, a regulatory posture that drives patients toward unregulated international suppliers in the name of safety is not actually protecting anyone. The goal should be evidence, oversight, and access — in that order, without sacrificing any of the three.

Frequently Asked Questions

Are peptides approved by the FDA? 

Some are, including GLP-1 receptor agonists (semaglutide, tirzepatide), insulin, and a range of hormone-based therapeutics. The peptides under review at the July 2026 FDA meeting — including BPC-157, TB-500, CJC-1295, and others — are not FDA-approved drugs and will not become FDA-approved drugs as a result of this meeting. The meeting concerns compounding eligibility only.

What is the 2026 FDA approved peptide list? 

There is no single published list of FDA-approved peptides, but the category of formally approved peptide-based drugs includes GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound), insulin analogues, leuprolide, vasopressin analogues, oxytocin, and several others used in endocrinology and oncology. None of the seven compounds under July review are on this list.

What is the difference between FDA approval and compounding eligibility? 

FDA drug approval is a full review process involving Phase I–III clinical trials, demonstrated safety and efficacy in humans, and post-market surveillance obligations. Compounding eligibility means a licensed pharmacy can legally prepare a substance for an individual patient under a physician's prescription. Compounded drugs are not FDA-approved and carry no manufacturer accountability or validated dosing protocol.

Is BPC-157 FDA approved in 2026? 

No. BPC-157 has never received FDA drug approval. As of April 2026, it remains on the Category 2 restricted compounding list pending the July advisory panel review. Even if reclassified, it will not be FDA-approved — it will simply be eligible for legal compounding with a prescription.

Is TB-500 legal in the United States? 

TB-500 is not a DEA-scheduled controlled substance, so possession is not illegal in the way that anabolic steroids are. However, its legal compounding for patient use was prohibited under the 2023 Category 2 designation. Whether that prohibition will be lifted depends on the outcome of the July 2026 advisory meeting. It is banned as a doping substance by WADA and most major professional sports organizations.

Can I get peptides from a compounding pharmacy without a prescription? 

No. Even if certain peptides are reclassified to Category 1, they remain prescription-only. A valid prescription from a licensed provider is required. Any pharmacy or vendor offering injectable peptides without a prescription is operating outside legal regulatory frameworks.

What happens if the FDA restricts peptides again after July 2026? 

If the advisory panel votes against reclassification, or if a future administration revisits the question, these compounds could return to Category 2 restriction. Regulatory status for compounded substances can change — which is one reason clinical observers caution against building long-term treatment plans around compounds that lack formal approval.

Why did the FDA restrict peptides in the first place? 

In 2023, the FDA placed approximately 17–19 peptides on the Category 2 restricted list citing safety concerns: potential carcinogenicity, immunogenicity risk, organ toxicity, and a lack of clinical trial data in humans. The agency's advisory panel voted in support of the restrictions at the time, though several of those advisers and internal staff no longer work for the agency.

Are peptides in protein powders and gummies regulated? 

When peptide ingredients are incorporated into dietary supplements, they fall under a different — and considerably less rigorous — regulatory framework than pharmaceutical compounding. Supplement manufacturers are not required to demonstrate safety or efficacy before bringing products to market, and quality control varies enormously. At the July meeting's margins, industry groups are also pushing to expand the federal definition of dietary supplements to include peptides more broadly. This is a parallel regulatory question patients should watch.

What does Category 2 classification actually mean? 

Category 2 is the FDA's designation for bulk drug substances nominated for compounding consideration that have been identified as presenting potential safety risks and are currently ineligible for routine compounding under Section 503A. A Category 2 designation is not a criminal prohibition or a formal drug ban — it is a compounding restriction. Patients can legally possess these substances; pharmacies cannot legally compound them for patient use.

Bottom Line

The FDA's July 2026 advisory meeting is a consequential regulatory moment — one that has been building since the 2023 restrictions and has been accelerated by a political environment unusually sympathetic to the compounding industry and wellness sector.

Three things are true simultaneously: the gray market created by the 2023 restrictions poses real risks to patients. The absence of Phase III human clinical trial data for these compounds is a genuine clinical gap, not a bureaucratic formality. And the political pressure shaping the July meeting's composition and likely direction raises legitimate questions about whether the process will produce a scientifically grounded outcome.

Patients deserve clear information in the middle of all that noise. The compounds under review are not FDA-approved and will not become so this summer. The outcome of the meeting will determine whether licensed pharmacies can legally compound them with a prescription — a meaningful distinction from the current reality, but a far cry from the clinical certainty that formal drug approval provides.

If you are navigating decisions about metabolic health, hormonal optimization, or recovery, the most durable foundation is not a single compound — it is a clear picture of your underlying biology. Start with a comprehensive metabolic panel, work with a clinician who interprets that data in the full context of your health, and use the next few months — while the regulatory process plays out — to build that foundation.

We will update this article following the July advisory vote.

This article is for informational and educational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before making any changes to your medication or supplement protocol. Regulatory status is subject to change; verify current FDA guidance at FDA.gov.

The article will be updated following the July 2026 FDA Pharmacy Compounding Advisory Committee vote.